Acalabrutinib (Calquence)
Drug timelines are a Plus or Pro feature.
6 regulatory and trial events tracked for Acalabrutinib (Calquence), covering 2022-09-19 to 2026-04-16. Get the full timeline:
Most recent: Clinical Trial Update: Acalabrutinib, Lenalidomide, and Rituximab for the Treatment of CD20 Positive Stage III-IV, Grade 1-3a Follicular Lymphoma [Phase 2]